Drugs / AB801
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07619313 | Jun 2026 → Jun 2027 expected | cholangiocarcinoma, pancreatic ductal adenocarcinoma | Jonsson Comprehensive Cancer Center | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06120075 | Jan 2024 → Nov 2026 expected | — | Arcus Biosciences, Inc. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06004921 | Oct 2023 → Feb 2024 | cancer | Arcus Biosciences, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AB801 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06120075 ↗ |
| Known as | Ligritinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07619313 ↗ |
| Route | Oral | “Participants will receive AB801 orally daily” NCT06120075 ↗ |